Epitope Analysis of Span-1 and DUPAN-2 using Synthesized Glycoconjugates Sialyllact-N-Fucopentaose II and Sialyllact-N-Tetraose

Kawa, Shigeyuki; Tokoo, Masuo; Oguchi, Hisao; Furuta, Seiichi; Homma, Tatsuji; Hasegawa, Yasuhisa; Ogata, Hiroyasu; Sakata, Kazuto

doi:10.1097/00006676-199411000-00003

Cited by 58 publications

(35 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings suggest the usefulness of this marker for screening pancreatic cancer patients on their first hospital visit. Although the epitope recognised by the monoclonal antibody (MAb) C242 used in this assay system has not yet been fully elucidated, C242 showed unique characteristics in that it has no reactivity to sialosyl-fucosyl-lactotetraose (sialyl Lewisa) or sialosyl-lactotetraose (sialyl Lewisc) (Johanson et al, 1991b;Kuusela et al, 1991), whereas MAbs for established tumour markers useful for diagnosis of pancreatic cancer were confirmed to have reactivities to either or both structures; NS19-9 for sialyl Lewisa, DUPAN-2 MAb for sialyl Lewisc, C50 and Span-1 MAb mainly for sialyl Lewisa and in part for sialyl Lewisc (Magnani et al, 1982;Nilsson et al, 1985;Kawa et al, 1994b).…”

mentioning

confidence: 99%

Comparative study of CA242 and CA19-9 in chronic pancreatitis

Furuya

Kawa²,

Hasebe³

et al. 1996

Br J Cancer

View full text Add to dashboard Cite

Summary CA242 has been proved to be useful in the diagnosis of pancreatic cancer. The aim of the present study was to clarify the mechanisms contributing to the high specificity of CA242 as compared with CA19-9 resulting from scarce serum elevation of this antigen in patients with chronic pancreatitis by correlating serum levels and endoscopic retrograde choledocho-pancreatography (ERCP) findings and by immunohistochemical analysis. Serum CA19-9 levels were significantly elevated in patients with calcification and with main pancreatic duct (MPD) stenosis or obstruction. On the other hand, serum CA242 levels showed no significant elevation in patients with such factors. Even though such pathological conditions were considered to lead to the stagnation of pancreatic juice, serum CA242 levels seemed to be less affected than serum CA19-9 levels. Immunohistochemical studies of chronic pancreatitis tissues revealed that CA242 was expressed less frequently and less intensely than CA19-9, and the difference in expression was more prominent in the centroacinar cells and terminal ductules. From the results of the present study, it is conceivable that CA242 is less influenced by the stagnation of the pancreatic juice than CA19-9 because of the low levels of expression in ductal systems, which results in the release of this antigen into the circulation in lower amounts than that of CA19-9.

show abstract

mentioning

confidence: 99%

Comparative study of CA242 and CA19-9 in chronic pancreatitis

Furuya

Kawa²,

Hasebe³

et al. 1996

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…In addition, the two markers had almost the same sensitivity for this malignancy. 26 In our study, although DUPAN-2 was not used as a marker for assessment of early confirmation of disease progression, SPan-1 was found to be as useful a marker as CA19-9 for the evaluation of disease control. In fact, SPan-1 could detect treatment failure earlier than RECIST criteria in 59% of the cases (Table 2-B).…”

Section: Discussion;mentioning

confidence: 51%

Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemotherapy

Tsutsumi

Kawamoto

Hirao³

et al. 2012

Pancreatology

View full text Add to dashboard Cite

show abstract

“…The carbohydrate antigens, recognized by the DU-PAN-2 and CA19-9 antibodies, are defined as sialyl Lewis c (Le c ) and sialyl Lewis a (Le a ), respectively [6,7] (Fig. 1).…”

Section: Introductionmentioning

confidence: 99%

“…DU-PAN-2 and CA19-9 expressions are also involved in ABH (O) antigens synthesis [15]. Since 5~10% of the Japanese population are considered to lack the Le enzyme, CA19-9 is less useful to them as a tumor marker due to its negative expression [6,7,11]. Generally, therefore, individuals negative for Le a and Le b due to a lack of the Le enzyme are anticipated to show an increase of serum DU-PAN-2 in those carcinomas [6,21].…”

Section: Introductionmentioning

confidence: 99%